07:00 , Jun 6, 2005 |  BioCentury  |  Finance

Ebb & Flow

Two droughts were ended last week in the U.S., as there was a completed IPO and a proposed follow-on. It's the first activity in the U.S. public equity markets since the end of the first...
07:00 , May 23, 2005 |  BioCentury  |  Finance

U.S. investment in Europe

U.S. investment in Europe Company Name Country Raised Investors Arpida Switzerland $67.4 Swissfirst; Temasek Capital; Carnegie Asset Management; CDIB BioScience Ventures; CITA; MVI Medical Venture Investments; Schroder Ventures Life Sciences; Alta Berkeley Associates; Aventic; BioMedinvest;...
08:00 , Feb 21, 2005 |  BioCentury  |  Finance

Ebb & Flow

The last time FibroGen raised money was a $56.5 million series E round in September 2000 - shortly after the genomics bubble burst. That left the prelinical company with a hefty post-money valuation around $280...
08:00 , Feb 14, 2005 |  BC Extra  |  Financial News

Jerini raises EUR 15.5M

Jerini (Berlin, Germany) raised EUR 15.5 million ($19.9 million) in a second closing of its June 2004 series B round, bringing to EUR 46.5 million the total raised in the round. Investors in the second...
08:00 , Jan 24, 2005 |  BioCentury  |  Finance

Tracking Epigenomics

Tracking Epigenomics Companies have long had to worry about their share prices when venture holdings came off lockup after IPOs. Increasingly, companies and investors have been working to avoid this, an example being Epigenomics (FSE:ECX),...
08:00 , Jan 3, 2005 |  BioCentury  |  Finance

Value-driven in Europe

As in the U.S., there was little in the way of momentum investing in Europe last year, with value investors picking their shots to provide a decent 2004. This year looks to be more of...
08:00 , Dec 6, 2004 |  BioCentury  |  Finance

Ebb & Flow

Companies and bankers are starting to think that an IPO window will open in Europe next year, and a few companies are starting to prepare for the blessed event. U.K.-based endocrine and musculoskeletal company ProStrakan...
08:00 , Dec 21, 2000 |  BC Extra  |  Financial News

Oxagen nets 30 million

Oxagen (Abingdon, U.K.), which is discovering disease-related genes, netted 30 million ($44.2 million) in private financing through Schroder Ventures; Abingworth; 3i Bioscience Investment Trust and 3i Group plc; BankInvest; CSFB Private Equity; Invesco; Oppenheimer Funds;...
08:00 , Dec 19, 2000 |  BC Extra  |  Financial News

Molecular Staging raises $41.3 million

Molecular Staging (New Haven, Conn.), which is developing protein and nucleic acid detection technologies, raised $41.3 million in a private financing. Investors included Investor AB; OrbiMed; CIBC Capital Partners; Cooper Hill Partners; Domain Partners III;...
07:00 , Aug 2, 2000 |  BC Extra  |  Financial News

Morphochem raises EUR40.7 million

Morphochem (Munich, Germany) raised EUR40.7 million ($37.5 million) through a private placement. The company, which specializes in protein-protein interaction and proteomics drug discovery, said the round included existing investors Techno Venture Management; Alta Partners; IKB...